Hugo Van Aken focuses on Anesthesia, Surgery, Hemodynamics, Internal medicine and Intensive care medicine. His study in Local anesthetic, Perioperative, Bupivacaine, Sufentanil and Propofol falls under the purview of Anesthesia. His work deals with themes such as Acute kidney injury and Analgesic, which intersect with Surgery.
His Hemodynamics research incorporates elements of Mean arterial pressure, Blood flow, Septic shock, Sepsis and Shock. His study in Internal medicine is interdisciplinary in nature, drawing from both Endocrinology and Cardiology. His Intensive care medicine research is multidisciplinary, incorporating elements of Prospective cohort study, Ticagrelor, Neuraxial blockade and Antithrombotic.
His main research concerns Anesthesia, Internal medicine, Surgery, Hemodynamics and Cardiology. His work in Anesthesia covers topics such as Septic shock which are related to areas like Shock. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology.
His Surgery study focuses on Local anesthetic in particular. His research integrates issues of Blood flow, Norepinephrine, Oxygen transport and Blood pressure, Heart rate in his study of Hemodynamics. His research on Cardiology focuses in particular on Artery.
His primary areas of study are Anesthesia, Surgery, Internal medicine, Intensive care medicine and Resuscitation. His specific area of interest is Anesthesia, where Hugo Van Aken studies Perioperative. His Surgery study incorporates themes from Acute kidney injury and Cohort study.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Hydroxyethyl starch and Cardiology. His studies deal with areas such as Prospective cohort study, Randomized controlled trial, MEDLINE and Anesthesiology as well as Intensive care medicine. The various areas that Hugo Van Aken examines in his Microcirculation study include Hemodynamics and Shock.
Hugo Van Aken mainly focuses on Intensive care medicine, Cardiopulmonary resuscitation, Acute kidney injury, Medical emergency and Resuscitation. His Intensive care medicine research includes elements of Prospective cohort study, Blood management, Etiology and MEDLINE. Hugo Van Aken combines subjects such as Cardiac surgery, Randomized controlled trial, Surgery, Renal replacement therapy and Kidney disease with his study of Acute kidney injury.
His work focuses on many connections between Randomized controlled trial and other disciplines, such as Anesthesiology, that overlap with his field of interest in Severity of illness. His Surgery research incorporates themes from Internal medicine and Renal function. His Kidney disease research includes themes of Anesthesia, Stroke, Myocardial infarction and Ischemia, Ischemic preconditioning.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial
Alexander Zarbock;John A. Kellum;Christoph Schmidt;Hugo Van Aken.
JAMA (2016)
Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
Melanie Meersch;Christoph Schmidt;Andreas Hoffmeier;Hugo Van Aken.
Intensive Care Medicine (2017)
Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology.
Wiebke Gogarten;Erik Vandermeulen;Hugo Van Aken;Sibylle Kozek.
European Journal of Anaesthesiology (2010)
Impact of epidural analgesia on mortality and morbidity after surgery: systematic review and meta-analysis of randomized controlled trials.
Daniel M. Pöpping;Nadia Elia;Hugo K. Van Aken;Emmanuel Marret.
Annals of Surgery (2014)
Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage
Elmar Berendes;Michael Walter;Paul Cullen;Thomas Prien.
The Lancet (1997)
Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study.
Bertrand Guidet;Bertrand Guidet;Olivier Martinet;Thierry Boulain;Francois Philippart.
Critical Care (2012)
Hydroxyethyl starches: different products--different effects.
Martin Westphal;Michael F. M. James;Sibylle Kozek-Langenecker;Reto Stocker.
Anesthesiology (2009)
The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways.
Edward Conway;Marlies Lutgart Julien Van de Wouwer;Saskia Pollefeyt;Kerstin Jurk.
Journal of Experimental Medicine (2002)
Remifentanil: a novel, short-acting, mu-opioid.
Hartmut Burkle;Stuart Dunbar;Hugo Van Aken.
Anesthesia & Analgesia (1996)
Effect of remote ischemic preconditioning on kidney injury among high-risk patients undergoing cardiac surgery: a randomized clinical trial.
Alexander Zarbock;Christoph Schmidt;Hugo Van Aken;Carola Wempe.
JAMA (2015)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Münster
The University of Texas Medical Branch at Galveston
University of Erlangen-Nuremberg
Université Paris Cité
La Jolla Institute For Allergy & Immunology
University of Pittsburgh
Erasmus University Rotterdam
University of Münster
Karolinska Institute
Université Libre de Bruxelles
University of Illinois at Urbana-Champaign
University of Wisconsin–Madison
National Research Council Canada
Stockholm University
University of Bologna
Peking University
University of Nottingham
The University of Texas MD Anderson Cancer Center
University College London
McGill University Health Centre
National Institute of Genetics
Grenoble Alpes University
University of Leeds
University of British Columbia
Heidelberg University
The University of Texas MD Anderson Cancer Center